Redefining Interventional Oncology

Redefining Interventional Oncology

Lipiodol® Ultra-Fluid
(Iodinated ethyl esters of fatty acids of poppy seed oil)

Guerbet is committed for more than 40 years in Interventional Oncology. Lipiodol® TransArterial ChemoEmbolization has an impact on prolonging the survival of selected patients with unresectable hepatocellular carcinoma (1;2). Since, thanks to a close collaboration with physicians from all over the world, HCC treatment evolved. By regenerating cTACE technique through procedure standardization and super selective catheterization approach (3), patient overall survival is positively impacted(3) and in specific cases*, a patient having a HCC with an irregular margin suggesting the absence of a pseudo capsule showing a well controlled tumor after 6 years (4) , or in a patient presenting originally three tumor-feeders, showing a well controlled tumor after 10 years and 4 months(5) HCC treatment is still evolving with immunotherapy development. Here again, Guerbet is working in collaboration with international physicians to highlight the contribution of a combined treatment strategy for the benefit of patients. To strengthen its involvement with the medical community in the treatment of HCC, Guerbet is developing LIVERLINKTM: Delivering a unique integrated solution for confident in HCC management.

*These specific cases are based on the results achieved in unique scientific or clinical setting. Individual results may vary because each patient and case are unique, there is no guarantee of any particular result for any specific patient


  1. Lo, C.M.; Ngan, H.; Tso, W.K.; Liu, C.L.; Lam, C.M.; Poon, R.T.; Fan, S.T.; Wong, J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35, 1164–1171.​
  2. Llovet, J.M.; Real, M.I.; Montaña, X.; Planas, R.; Coll, S.; Aponte, J.; Ayuso, C.; Sala, M.; Muchart, J.; Solà, R.; et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002, 359, 1734–1739.
  3. Thierry de Baere et al. Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE) Cardiovasc Intervent Radiol (2022) 45:1430–1440
  4. Shiro MiyayamaMD, and Osamu Matsui, MD SuperselectiveConventiona Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome J Vasc. Interv. Radiol. 2016; 27:1269–1278​
  5. Shiro Miyayama Ultraselective conventional transarterial lchemoembolization: When and how? Clinical and Molecular Hepatology 2019; 25:344-353